glp 1 orforglipron Oral GLP-1: Clinical Progress and Insights Foundayo (Orforglipron): What to Know

Even if your company is implementing its 2026 strategy, there are still steps you can take to control expenses while maintaining affordable and high-quality care for your employees

Quick look at the key results According to clinical trial investigators, orforglipron: Led to significant weight reduction across all dosing groups Showed greater effects at the highest dose levels Helped lower blood sugar in people with diabetes Supported modest improvements in blood pressure Demonstrated mainly mild to moderate side effects The trial results suggest that the once-daily pill performs competitively with early GLP-1 injection studies

Structural Basis for GLP-1 Receptor Activation by LY3502970, an Orally Active Nonpeptide Agonist

Rev Diabet Stud

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas